Proposed Subscription and Retail Offer; Update
EMV Capital raises up to £1.5m through subscription and retail offer at 50p per share.
- Fundraising amount up to £1.5 million
- Issue price per share £0.50
- Premium to closing price approximately 15%
- Assets under management £100 million
- Fair value of direct holdings £41 million
- Fair value of managed holdings £65.7 million
Select text to share a quote on X · sign in to keep highlights & notes in your EMVC notes
Update on financial operations and the portfolio
EMV Capital plc (AIM: EMVC), the deeptech and life sciences VC investment group, today announces its intention to raise up to £1.5 million (Fundraising) through a proposed subscription by, and retail offer to, new and existing investors for new ordinary shares in the capital of the Company (New Shares) at an issue price of £0.50 per New Share (Issue Price). The Issue Price represents a premium of approximately 15 per cent. to the closing mid-market price of 43.5 pence per ordinary share in the capital of the Company on 2 December 2024 (the latest practicable date prior to the publication of this announcement).
A further announcement will be made by the Company shortly regarding the Retail Offer (as defined below) and its terms. It is expected that the Retail Offer will launch today, 3 December 2024, shortly after this Announcement and will be open for applications up to 4.30 p.m. on 4 December 2024, or such later time and date as the Company and Winterflood Securities Limited (Winterflood) may agree. The result of the Retail Offer is expected to be announced by the Company on or around 5 December 2024. For the avoidance of doubt, the Retail Offer is in addition to, and conditional upon the completion of, the Subscription. There can be no guarantee that the Retail Offer will be fully subscribed.
The Fundraising will be effected pursuant to the existing authorities to allot equity securities granted at the Company's annual general meeting on 10 July 2024.
Background to and reasons for the Fundraising
EMV Capital is positioning itself to become a leading venture capital (VC) investment group, specialising in the deeptech and life sciences sectors. The Company aims to deliver shareholder value by identifying and investing in companies with transformative technologies both within the UK and internationally.
The Group's strategy focuses on achieving capital returns through the profitable exits of selected portfolio companies, as well as generating carried interest from its growing Funds practice. An example of this approach is demonstrated through the strong performance of the Group's Venture Building programme. Over the past two years, this initiative has driven significant growth in the fair value of EMV Capital's direct holdings, notably in the following cohort portfolio companies to a total of £7.1 million, achieved with an initial total investment of just £0.4 million in cash, complemented by £0.4 million of in-kind services. This performance highlights EMV Capital's ability to create significant value with a disciplined and innovative approach to investment.
| Portfolio company | Business sector | Direct FV increase |
| Deeptech Recycling Technologies | Plastic waste recycling | £1.8 million |
| DName-iT | Lab blood verification | £1.6 million |
| Ventive | Heat pump developer | £0.9 million |
| Vortex Biosciences | Liquid biopsy/oncology | £2.8 million |
| Total | - | £7.1 million |
In the first half of 2024, EMV Capital achieved a significant milestone, surpassing £100 million in assets under management (AUM). This coincided with the successful launch of the Company's Fund Management practice. As announced on 30 September 2024 in its interim results for the six months ended 30 June 2024 (Interim Results), the Company's AUM comprised a fair value of £41 million in directly owned holdings and £65.7 million in managed and third-party holdings. EMV Capital's portfolio now spans over 70 companies, bolstered by the May 2024 mandate to manage the Cambridge-based Martlet Capital portfolio.
The Company is progressing its strategy to achieve operational self-sufficiency by covering most, if not all, core costs through recurring fund management fees, value creation services, corporate finance activities, and other income streams. The Directors have identified a route to break-even, targeting recurring annual fund management fees of over £1 million. This will be supported by a targeted increase of £30 million to £50 million (or more) in AUM during 2025/26.
As outlined in the annual accounts for the period ending 31 December 2023, the Group, including its subsidiaries, identified a cash requirement of approximately £3.6 million to fund operations through to June 2025. Of this, the core operating business (excluding consolidated portfolio company subsidiaries Glycotest, ProAxsis and CetroMed, which are expected to secure third party funding), requires £1.6 million. The Company noted that funding sources could include fee income, the sale of portfolio assets or a share placement. Additionally, the Company has explored debt financing options, including the potential availability of a £750,000 facility.
The Directors have carefully evaluated all funding options available to the Company, taking into account current asset values, debt financing costs, the Company's share price, and the potential dilutive effects of equity placements. Ultimately, the Directors concluded that a targeted Fundraising represents the optimal solution, enabling the Company to strengthen its balance sheet, continue growing the fair value of its directly held assets, and maintain a low debt position. This approach means that over the next 12 months the Group will remain well-positioned for sustainable growth and long-term value creation.
Update on financial operations and the portfolio
Since the announcement of the Company's Interim Results, the Company is pleased to provide the following update on its financial operations and the portfolio:
Group 'core' income and losses
o Unaudited Group 'core' income for the ten month period to 31 October 2024 is c.£2 million (as compared to £1.2 million for the full year ended 31 December 2023). This is split as to £0.9 million for services fees, £0.6 million for fundraising fees, and £0.5 million for fund management fees.
o Unaudited Group 'core' losses for the ten month period to 31 October 2024 are c.£1.1 million (as compared to £1.1 million for the full year ended 31 December 2023).
o Group 'core' excludes subsidiary portfolio companies (Glycotest, ProAxsis and CetroMed), which are financed by third party investors.
Wanda Connected Healthcare Systems
As announced on 28 May 2024, the Group acquired a 30 per cent. direct holding in Wanda for c.£62,000 paid for by in-kind services. Benefiting from the Group's value creation services as a member of the Venture Building programme, Wanda is expected to complete a c.£1 million equity investment round on 6 December 2024 at a pre-money valuation of £5 million. Following completion of that investment round, the fair value of the Group's fully diluted holding will be £1.35 million, a 21.5x increase. Further details of this transaction, including the Group's new direct shareholding and third party assets under management, are anticipated to be announced on or around 9 December 2024.
Q-Bot
As announced on 30 July 2024, Q-Bot raised £1.5 million to progress its revised business plan, which included rationalising its business into two separate divisions, an installations business and a technologies focused business. The planned restructuring has experienced a delay in execution and a refined business plan, with Q-Bot having launched on 2 December 2024 a further fundraising programme of c.£1.3 million to complete its pivot to a technology and partnerships focused business, and its exit from direct services.
The Q-Bot fundraising is by way of a convertible loan note and advance subscription agreement, each on advantageous conversion terms with a conversion price substantially lower than the previous price per share. The Group intends to participate with a direct investment of c.£0.31 million, which it intends to settle within a two week period by way of conversion of receivables (c.£60,000) and the issue of shares in EMV Capital (c.£0.25 million). Should EMV Capital shares be issued, it is anticipated that the price per EMV Capital share would be the higher of: (i) the middle-market closing price for EMV Capital shares on the day before the investment; and (ii) the average middle-market closing price for EMV Capital shares over the 12 month period preceding its investment (which, for example, is 62.3 pence as at 2 December 2024, the latest practicable date prior to the publication of this announcement). In addition, these shares, if issued, would be subject to orderly market provisions such that if they are disposed of they must be sold through the Company's broker.
As the proposed Q-Bot fundraising does not establish a fixed price (given that the conversion price of the convertible instruments is contingent upon factors such as a subsequent fundraising round, an exit event, or the maturity date), the Directors are unable to estimate any changes to the current fair value of Q-Bot upon completion of the fundraising. However, in the absence of significant growth prior to its next equity fundraising, it is anticipated that the fair value of Q-Bot could be materially lower than the previously reported figure.
Use of proceeds
The net proceeds from the Fundraising, in combination with the Group's fee income, are intended to be utilised over the next 12 months to:
- provide ongoing working capital to support the Company's day-to-day operations;
- develop and enhance investor reporting infrastructure for EMV Capital Partners (EMVCP), the Company's wholly owned corporate finance and venture capital firm, in response to the continued growth of its syndicated investor base and Fund management activities;
- drive growth through strategic hires to strengthen the Company's operational and strategic capabilities; and
- bolster balance sheet strength and maintain 'dry powder' for capital efficient investments, with a particular focus on future Venture Building initiatives.
This use of funds is designed to ensure EMV Capital remains well-positioned for sustained growth, operational efficiency, and continued value creation.
Details of the Fundraising
General details
EMVCP, acting as bookrunner, has introduced certain new and existing investors who intend to participate in the Fundraising, both through the Subscription and the Retail Offer (each as defined below). It is anticipated that such investors will subscribe for up to 3,000,000 New Shares at the Issue Price to raise up to £1.5 million.
The Fundraising comprises:
- a subscription by new and existing investors at the Issue Price for 1,760,000 New Shares (Subscription Shares) raising £880,000 (Subscription); and
- the Company intends to launch a retail offer through the Winterflood Retail Access platform (WRAP) for qualifying retail investors in the UK to subscribe for up to 1,240,000 New Shares at the Issue Price (Retail Offer Shares) to raise up to a further £620,000 (Retail Offer).
The issue of New Shares will be pursuant to the Directors' existing authority to allot ordinary shares in the capital of the Company, as provided at its 2024 annual general meeting.
The Issue Price represents a premium of approximately 15 per cent. to the closing mid-market price of 43.5 pence per ordinary share in the capital of the Company on 2 December 2024, being the latest practicable date prior to the publication of this announcement.
The Fundraising is not being underwritten.
The New Shares, when issued, will be fully paid and will rank pari passu in all respects with the rest of the Company's ordinary share capital.
Director / PDMR and substantial shareholder participation
Certain Directors, being Charles Spicer (Non-Executive Chair), Ilian Iliev (Chief Executive Officer) and Ed Hooper (Executive Director), and members of the Company's senior management team (PDMRs) intend to participate in the Fundraising, both through the Subscription and the Retail Offer, for an aggregate subscription amount of approximately £245,000 through the issue of 490,000 New Shares at the Issue Price.
It is also anticipated that A Beckman plc SSAS (Small Self Administered Pension Scheme), which is associated with Melvin Lawson, a substantial shareholder in the Company, will participate in the Fundraising through the Subscription (Substantial Shareholder Participation). It is anticipated that the Substantial Shareholder Participation will comprise approximately £50,000 through the issue of 100,000 New Shares at the Issue Price.
Further details will be announced as appropriate in due course.
Subscription
The Subscription is not conditional upon the completion of the Retail Offer.
The timing of the closing of the Subscription and the allocation of the Subscription Shares is to be determined at the discretion of the Company. A further announcement confirming final details of the Subscription will be announced as soon as practicable after the closing of the bookbuilding process in respect of the Subscription, anticipated to be on 3 December 2024.
Retail Offer
The Directors believe it to be important to provide existing shareholders and qualifying retail investors in the United Kingdom with an opportunity to participate in the Fundraising and to subscribe for New Shares.
A further announcement will be made by the Company shortly regarding the Retail Offer and its terms. It is expected that the Retail Offer will launch today, 3 December 2024, shortly after this announcement and will be open for applications up to 4.30 p.m. on 4 December 2024, or such later time and date as the Company and Winterflood may agree. The result of the Retail Offer is expected to be announced by the Company on or around 5 December 2024. For the avoidance of doubt, the Retail Offer is in addition to the Subscription. There can be no guarantee that the Retail Offer will be fully subscribed. The Retail Offer is conditional upon completion of the Subscription.
Admission
Application will be made to London Stock Exchange plc for the admission to trading on AIM of the Subscription Shares and such number of Retail Offer Shares as are subscribed for pursuant to the Retail Offer (Admission). It is expected that Admission will become effective and dealings will commence at 8.00 a.m. on or around 9 December 2024.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.